MNPR 8-K: SEC filing

Monopar Therapeutics

Filed with the SEC on Nov 12, 2026 · accession 0001437749-26-036385

MNPR filed a 8-K (current report) with the SEC on Nov 12, 2026. A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Summary of the filing

Monopar Therapeutics issued a press release announcing its financial results for the third quarter ended September 30, 2026, furnished under Item 2.02 of Form 8-K.

For details, click here →How to read a 8-K →

Key details

RegistrantMonopar Therapeutics Inc.

Chief financial officerQuan Vu

✦ Ask GOAX AI about this filing — what it means for MNPR, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for MNPR?

Click here

Frequently asked questions

What did MNPR file with the SEC on Nov 12, 2026?

MNPR filed a 8-K (SEC filing). Monopar Therapeutics issued a press release announcing its financial results for the third quarter ended September 30, 2026, furnished under Item 2.02 of Form 8-K.

How do I read a 8-K?

A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Other MNPR SEC filings

Get alerts when MNPR files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days

MNPR overview MNPR analysis MNPR news Latest SEC filings